Cardiogen: Complete Research Profile — Khavinson Cardiac Bioregulatory Tetrapeptide (AEDR) for Heart Tissue Research (2026)

# Cardiogen: Complete Research Profile — Khavinson Cardiac Bioregulatory Tetrapeptide (AEDR) for Heart Tissue Research (2026)

Cardiogen is a synthetic tetrapeptide developed within the Khavinson bioregulatory peptide program at the St. Petersburg Institute of Bioregulation and Gerontology. With the amino acid sequence Ala-Glu-Asp-Arg (AEDR), it is designed to target cardiac tissue — specifically cardiomyocytes (heart muscle cells) — and is proposed to modulate gene expression in cardiac tissue through an epigenetic mechanism involving chromatin interaction and DNA binding.

Unlike cardiovascular research compounds that act on receptors (adrenoceptors, angiotensin receptors, natriuretic peptide receptors), Cardiogen represents a fundamentally different pharmacological class: an ultra-short peptide proposed to directly modulate cardiac gene expression at the nuclear level.

This research profile provides complete coverage of Cardiogen's molecular characteristics, its proposed mechanism in cardiac tissue, published research findings, comparison with related bioregulators, and research considerations. As with all content on this platform, this article is educational only and does not constitute medical advice.

---

What Is Cardiogen?

Cardiogen is a synthetic tetrapeptide — a chain of four amino acids — with the sequence Ala-Glu-Asp-Arg (one-letter code: AEDR). Its systematic chemical name is H-Ala-Glu-Asp-Arg-OH, reflecting the free amino terminal (H-) and free carboxyl terminal (-OH) in its unmodified form.

The peptide was developed by Professor Vladimir Khavinson and colleagues as part of the systematic Khavinson bioregulator research program, which identified short peptide sequences from tissue-specific biological extracts and synthesized them as defined molecular entities for research investigation.

Cardiogen is part of the AED-family of Khavinson peptides, which share the Ala-Glu-Asp core sequence and differ in their C-terminal residue. This family includes:

• •Cartalax (AED, Ala-Glu-Asp) — cartilage/chondrocyte focus — complete profile here
• •Cardiogen (AEDR, Ala-Glu-Asp-Arg) — cardiac focus
• •Pinealon (EDR, Glu-Asp-Arg) — pineal/neural focus — complete profile here
• •Cortagen (AEDP, Ala-Glu-Asp-Pro) — cerebral cortex focus

The tissue specificity of each peptide — despite sharing a core AED sequence — illustrates the Khavinson hypothesis that even single amino acid changes can shift the DNA-binding complementarity and thus the tissue-targeting properties of ultra-short bioregulatory peptides.

Key Characteristics at a Glance

---

The Khavinson Bioregulator Framework

Cardiogen belongs to the Khavinson bioregulatory peptide class — a unique category of ultra-short, tissue-specific synthetic peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s.

For a comprehensive introduction to this class, including the full peptide table, history, and detailed mechanism discussion, see the Khavinson Bioregulatory Peptides: Complete Guide.

Key class characteristics relevant to Cardiogen:

• •Epigenetic mechanism: Proposed to function by entering cell nuclei and directly modulating DNA and chromatin, rather than acting via surface receptor binding
• •Tissue specificity: The AEDR sequence is theorized to have specific complementarity to DNA regulatory sequences in cardiac tissue
• •Chromatin decondensation: Like other bioregulatory peptides, may act partly through reversal of age-related chromatin condensation in cardiac cells
• •Ultra-short length: At 4 amino acids, Cardiogen is small enough to potentially traverse nuclear pore complexes without classical nuclear transport machinery

---

Cardiac Tissue: What Cardiogen Is Designed to Target

Cardiomyocyte Biology

The heart is one of the most metabolically demanding organs in the body, driven almost entirely by cardiomyocytes — the highly specialized, contractile muscle cells that make up the bulk of cardiac tissue. Unlike skeletal muscle cells, mature cardiomyocytes have limited proliferative capacity; the human heart contains approximately 2–4 billion cardiomyocytes, and adult cardiomyocytes rarely divide.

This limited regenerative capacity means that:

• •Cardiomyocyte loss (from infarction, toxicity, or aging) is poorly compensated
• •Aging-related decline in cardiomyocyte function directly impacts cardiac performance
• •Interventions that support cardiomyocyte gene expression and reduce apoptosis are of significant research interest

Key cardiomyocyte characteristics:

• •Terminally differentiated: Most cardiomyocytes in adults do not divide
• •Highly organized cytoskeleton: Sarcomere proteins (actin, myosin, titin) are tightly regulated by tissue-specific gene programs
• •Metabolic dependence: Cardiomyocytes derive ~70% of energy from fatty acid oxidation; metabolic gene programs are age-regulated
• •Electrical integration: Gap junctions (connexins) coordinate electrical coupling and contraction

Age-Related Cardiac Changes

As organisms age, cardiac tissue undergoes characteristic changes that impair function:

• •Cardiomyocyte hypertrophy (enlargement) as compensation for functional decline
• •Increased apoptosis — elevated cardiomyocyte death with inadequate replacement
• •Fibrosis — replacement of functional myocardium with connective tissue
• •Reduced contractility — impaired calcium handling and sarcomere function
• •Gene expression shifts — re-expression of fetal cardiac gene programs (β-MHC, ANP) at the expense of adult programs (α-MHC)

Cardiogen research explores whether targeted peptide intervention can modulate these gene expression changes in aged cardiac tissue.

---

Proposed Mechanism of Action

Core Hypothesis

Cardiogen is proposed to act through the same epigenetic mechanism common to all Khavinson bioregulatory peptides: nuclear entry followed by direct interaction with cardiac-tissue-specific DNA regulatory elements.

The AEDR sequence is theorized to have complementarity to promoter or enhancer sequences that regulate key cardiac genes — cytoskeletal proteins, metabolic enzymes, and cell survival factors. By binding to these regulatory regions, Cardiogen would modulate the accessibility of those sequences to transcription factors, effectively tuning the expression of cardiac-specific gene programs.

Specific Molecular Effects in Cardiomyocytes

Published preclinical research from the Khavinson group documents specific effects of Cardiogen on cardiomyocyte biology:

1. Stimulation of Cardiomyocyte Proliferation

In cell culture experiments using cardiac tissue from young (3-month-old) and aged (24-month-old) rats, Cardiogen was found to stimulate proliferative activity in cardiomyocytes from aged animals. This is particularly notable given the post-mitotic character of most adult cardiomyocytes — any pro-proliferative effect in this cell type represents a significant finding worthy of further investigation.

Proliferative activity was assessed using Ki-67 immunostaining, a standard marker of cells undergoing cell cycle progression. Cardiogen-treated aged cardiomyocyte cultures showed increased Ki-67 positivity compared to untreated controls.

2. Suppression of p53-Mediated Apoptosis

One of the most significant documented effects of Cardiogen in cardiac tissue research is its ability to suppress p53 protein expression and thereby reduce apoptotic activity in aged cardiomyocytes.

p53 (tumor suppressor protein 53) is a key regulator of the apoptotic response in stressed and aging cells. In aged cardiac tissue, elevated p53 activity contributes to cardiomyocyte loss through programmed cell death. Cardiogen treatment in aged rat cardiomyocytes reduced p53 protein levels, with a corresponding reduction in apoptotic markers.

This dual action — promoting proliferation while suppressing apoptosis — creates conditions that could support cardiomyocyte population maintenance in aging cardiac tissue.

3. Cytoskeletal Gene Accessibility

Khavinson's chromatin research framework suggests that Cardiogen acts on DNA-associated protein complexes governing the accessibility of genes encoding cytoskeletal proteins critical for cardiomyocyte function. These include:

• •Troponin subunits (cardiac-specific contractile regulation)
• •Alpha- and beta-myosin heavy chain (motor proteins)
• •Actin isoforms
• •Titin (sarcomere structural protein)

By increasing the chromatin accessibility of these gene loci, Cardiogen would support appropriate cardiac gene expression programs in aging cells.

4. Cardiac Metabolic Activity

Research suggests Cardiogen also promotes general metabolic activity in cardiac cells — supporting protein synthesis and cellular energy metabolism functions that decline with age.

---

Published Research Findings

Preclinical Studies

The primary published research on Cardiogen comes from preclinical studies conducted by Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology.

Comparative Young vs. Aged Cardiomyocyte Studies

The most cited Cardiogen research involves comparative studies in primary cardiomyocyte cultures from young and aged rats. Key findings:

• •Cardiogen preferentially activates proliferative markers (Ki-67) in aged cardiomyocyte cultures, with lesser effects in young cells (which already have adequate proliferative signaling)
• •p53 downregulation is more pronounced in aged cells, suggesting the peptide specifically counteracts age-related apoptotic signaling
• •Morphological changes consistent with improved cellular health were observed in treated aged cultures

DNA and Chromatin Interaction Studies

Consistent with the class-wide mechanism, molecular studies on Cardiogen include:

• •Electrophoretic mobility shift assays demonstrating formation of Cardiogen-DNA complexes
• •Binding studies with cardiac-tissue chromatin fractions
• •Analysis of histone interaction patterns

Research Gaps and Limitations

Important limitations of the current Cardiogen evidence base:

1. Species limitation: Available studies are in rodent models; no primate or human cardiac data is published

2. In vitro focus: Primary evidence is from cell culture models; in vivo cardiac studies are limited

3. Single source: Research is almost exclusively from the Khavinson group; independent replication has not been published

4. No clinical trials: No human clinical trials (Phase I, II, or III) for defined Cardiogen have been conducted

5. Mechanistic gaps: The precise DNA sequences with which AEDR interacts in cardiac promoters have not been fully characterized

---

Comparison With Related Bioregulators and Cardiac Compounds

Within the Khavinson Family

Cardiogen is the only Khavinson peptide specifically targeting cardiomyocytes. Vesugen (KED) addresses the vascular component of cardiovascular biology (endothelial cells, arterial walls) rather than the myocardium itself, making the two peptides complementary rather than overlapping in their proposed targets.

Compared to Other Cardiac Research Peptides

Cardiogen is distinct from other cardiac-focused research peptides in mechanism and target:

• •BPC-157: 15-amino acid peptide with regenerative and cardioprotective effects; acts through receptor-mediated pathways and angiogenesis promotion
• •Thymosin β-4 / TB-4: Promotes cardiomyocyte survival after injury; acts through actin cytoskeleton regulation and receptor-mediated pathways
• •ANP/BNP analogues: Natriuretic peptides acting through GC-A/GC-B receptors to modulate cardiac load

Unlike these compounds, Cardiogen's proposed mechanism bypasses surface receptors entirely, operating at the epigenetic level.

---

Research Considerations

Dosing in Research Contexts

Published Russian research on bioregulatory peptides, including related compounds, typically employs:

• •Administration routes: Subcutaneous injection (most common in preclinical studies); oral administration studied for some peptides
• •Dose ranges: Microgram to low milligram doses per administration in animal studies
• •Frequency: Often intermittent (not daily) based on the proposed gene expression regulation rather than receptor occupancy mechanism

Specific Cardiogen dosing protocols are not well-characterized in the English-language literature, and no clinical dosing recommendations can be made.

Research Purity Considerations

When working with Cardiogen in a research context:

• •Certificate of Analysis (CoA): HPLC purity ≥98% is standard for research-grade peptides
• •Sequence verification: Mass spectrometry confirmation of AEDR sequence
• •Storage: Lyophilized peptides should be stored frozen; reconstituted solutions used promptly or aliquoted and re-frozen

---

Frequently Asked Questions

Is Cardiogen the same as Cortagen?

No. Both are tetrapeptides with an AED core, but they differ in their fourth amino acid and tissue targets:

• •Cardiogen: AEDR → cardiac tissue
• •Cortagen: AEDP → cerebral cortex

Is Cardiogen the same as Vesugen?

No. Vesugen (KED) targets vascular endothelium — the inner lining of blood vessels — while Cardiogen (AEDR) targets cardiomyocytes — the contractile muscle cells of the heart itself. They address different components of the cardiovascular system.

What is the difference between Cardiogen and cardiac peptides like BPC-157?

BPC-157 is a 15-amino acid peptide with receptor-mediated mechanisms including angiogenesis promotion and cardioprotective effects via NO pathways. Cardiogen is a 4-amino acid peptide proposed to act through nuclear entry and direct gene expression modulation — a fundamentally different mechanism category.

Has Cardiogen been studied in humans?

Not in formal clinical trials. The available research is preclinical (cell culture and animal models), primarily from the Khavinson group.

---

Summary

Cardiogen (AEDR tetrapeptide) is the Khavinson bioregulatory peptide targeting cardiac tissue — specifically cardiomyocytes, the contractile muscle cells of the heart. Its proposed mechanism — direct nuclear entry and epigenetic modulation of cardiac gene expression — distinguishes it from receptor-mediated cardiovascular peptides and other cardiac research compounds.

Published preclinical evidence from the Khavinson group documents stimulation of cardiomyocyte proliferation, suppression of p53-mediated apoptosis, and support for cytoskeletal gene expression in aged cardiac cultures. These findings make Cardiogen a scientifically interesting candidate for research into cardiac aging biology, though independent replication and human safety/efficacy data are absent from the current literature.

For researchers investigating bioregulatory peptides in the context of cardiovascular aging, Cardiogen represents a distinct and under-studied target — particularly given the limited regenerative capacity of cardiomyocytes and the significant medical importance of age-related cardiac decline.

---

Further Reading:

• •Prostamax (KEDP Tetrapeptide): Complete Research Profile — Khavinson Prostate Bioregulator (2026)
• •Livagen (KEDA Tetrapeptide): Complete Research Profile — Khavinson Liver & Chromatin Decondensation Bioregulator (2026)
• •Cartalax: Complete Research Profile — Khavinson Tripeptide Bioregulator for Cartilage, Chondrocyte, and Joint Tissue Research
• •Vesugen (KED Tripeptide): Complete Research Profile — Khavinson Vascular Endothelium Bioregulator (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder

---

Related Articles:

• •Khavinson Bioregulatory Peptides: Complete Guide
• •Vesugen (KED): Vascular Endothelium Bioregulator
• •Pinealon (EDR): Pineal Gland & Neuroprotection

This article is for educational and research purposes only. Cardiogen is not an approved therapeutic agent. Nothing herein constitutes medical advice.